Join us for an expert-led webinar with Adham Ahmed as he delves into the intricacies of developing robust and reliable reversed-phase chromatography methods. This session will cover critical ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe adverse ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced the dosing of the first ...
SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
"Results from the Phase Ib study in U.S. informed and provided critical knowledge for our 13-week Phase IIa study design of ASC30 oral once-daily tablet. As a small molecule, ASC30 has the potential ...
- Linsitinib is the first and only oral small molecule therapy to establish statistical and clinical significance in Thyroid Eye Disease (TED) - Phase 2b/3 LIDS trial met primary endpoint of proptosis ...
Please provide your email address to receive an email when new articles are posted on . Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist to treat ALS failed to meet its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback